Omega Funds, a leading international healthcare venture capital firm focused on delivering impactful medicines to patients, is pleased to announce the promotion of Francesco Draetta to Managing Director. Francesco joins the Firm’s existing Managing Directors Claudio Nessi and Otello Stampacchia.

Francesco has led or co-led many of Omega’s investments, including Arcutis Biotherapeutics (IPO), Amunix Pharmaceuticals (acquired by Sanofi), Chord Therapeutics (acquired by Merck KGaA), and Lexeo Therapeutics (IPO), and was involved in the Firm’s investment in Gossamer Bio (IPO), as well as several undisclosed direct secondary transactions. Francesco is currently on the board of directors for Beta Bionics, NRG Therapeutics, and one of Omega’s stealth company creations, where he also served as founding CEO, and is a board observer at ARTBIO. He also co-leads the Firm’s fundraising efforts, which resulted in more than $1.1 billion raised across Omega Fund VI and Omega Fund VII.

“Francesco has been instrumental to Omega’s growth, particularly across our investment and fundraising activities," said Omega Founder and Managing Director Otello Stampacchia. “I am particularly proud of his development into a valuable leader and mentor within our team, a testament to his talent and dedication. We are very pleased to recognize his many contributions to the Firm with this promotion.”

“Francesco’s achievements and strong expertise, as well as his commitment to Omega’s values, have had positive impacts across all aspects of the Firm,” said Managing Director Claudio Nessi. “We look forward to his continued success as he assumes his new leadership responsibilities.”

From 2008 to 2012, Francesco was an Analyst at Omega. Prior to rejoining Omega in 2016, he was part of the investment teams of Commonfund Capital and Brookside Mezzanine Partners. Francesco is a CFA charterholder, a CAIA charterholder, a FRM, and holds a BBA in Finance and Operations Management from the Isenberg School of Management at the University of Massachusetts Amherst.

About Omega Funds

Founded in 2004, Omega Funds is a leading international venture capital firm that creates and invests in life sciences companies that target our world's most urgent medical needs. Omega focuses on supporting companies through value inflection points across the full arc of innovation, from formation through clinical and commercial milestones. Omega portfolio companies have brought 50 products to market in multiple therapeutic areas, including oncology, rare diseases, precision medicine and others. Visit www.omegafunds.com for additional information.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240104654819/en/

Katie Kerfoot
kk@omegafunds.com

Logo

Tags

More Like This

Ousia Pharma Secures Substantial Seed Financing Led by Omega Funds to Advance Groundbreaking Obesity Treatment

Giovanni Caforio Appointed Operating Advisor to CD&R Funds

Sofinnova Partners Raises $200M Digital Medicine Fund

Andreas Goppelt Appointed Managing Director of OrphaCare

FarmaMondo Group appoints Independent Board Director Natalie Douglas, global pharmaceutical managed access and commercialization pioneer

Sofinnova Partners Closes Oversubscribed €82 Million Sofinnova MD Start IV Fund to Create the Next Generation of Medtech Companies

Sofinnova Partners Exceeds Target With €165M Biotech Acceleration Fund, Europe’s Largest, With Strong Pharma Support

Galderma Announces Appointment of New Chief Financial Officer